- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01880957
PET and MRI Brain Imaging of Bipolar Disorder
Pathophysiology and Treatment of Bipolar Disorder as Assessed by in Vivo Imaging
The primary aims of this study are to:
- Quantify serotonin transporter (5-HTT) binding potential (BP) in vivo in bipolar disorder patients (BPD) during a major depressive episode (MDE).
- Assess the effect of lithium treatment of bipolar disorder on 5-HTT.
- Assess the effect of lithium treatment of bipolar disorder on 5-HT1A BP.
- Assess the effect of lamotrigine treatment of bipolar disorder on 5-HTT and 5-HT1A BP.
- Assess the effect of lithium treatment of unipolar depression on 5-HTT BP.
Study Overview
Status
Intervention / Treatment
Detailed Description
PET and MRI imaging will be used to investigate the aims described above in patients who have bipolar disorder or unipolar depression and are currently experiencing a depressive episode. Both healthy controls and depressed participants with bipolar disorder or unipolar depression will be recruited. Patients who are on medication before enrolling in the study will have a three week washout. At baseline, healthy controls and patients will have an MRI consisting of both structural and functional sequences. Psychological measures will also be obtained at baseline. Within one week of the MRI, both patients and healthy controls will have one CUMI and one DASB PET scan.
Following the baseline PET scans, patient participants will begin medication treatment with either lithium or lamotrigine, based on the clinical judgement of the treating psychiatrist. Psychological measures will be obtained every 2 weeks. After 6 weeks of medication treatment at a therapeutic dose, patients will be assessed for remission (defined as a 50% decrease in the HDRS score from baseline). If this criteria is met, patient participants will then have follow-up PET scans (one CUMI and one DASB). If this criteria is not met, the patient will be switched to the other medication under study and will be reevaluated after an additional 4 weeks of medication treatment. Patients who still do not demonstrate a 50% decrease in their HDRS will be considered non-responders and will have repeat CUMI and DASB scans.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Stony Brook, New York, United States, 11794
- Stony Brook University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PATIENTS
BIPOLAR
Inclusion Criteria:
- Bipolar patients suffering from a major depressive episode currently or recently (in the month prior to scanning). Patients on psychiatric medication will have failed their current regimen for the treatment of their depression: they will meet criteria for depression, be seeking treatment for it, and have been on an adequate dose of antidepressant or mood stabilizer (as defined by the Antidepressant Treatment Form-see Oquendo et al., 2003) for 4 weeks or more.
- Of sufficient severity to score at least 15 on the first 17 items of the Hamilton Depression Rating Scale or a score of 10 to 14 on the first 17 items of the Hamilton Depression Scale in conjunction with a score of at least 29 on the Beck Depression Inventory.
- Age range 18-65 years.
- Off all psychotropic and other types of drugs likely to interact with serotonin transporters and 5-HT1A receptors for at least 21 days. Allowed short-acting benzodiazepines for distressing anxiety or insomnia (up to 24 hours prior to each PET scan). Patients will be off neuroleptics for 3 weeks and off fluoxetine for 6 weeks prior to study. Off serotonin depleting drugs such as reserpine for 3 months. Patient will also be off anti-coagulant/anti-platelet treatment such as coumadin, with the exception of aspirin for 10 days.
- Willing to travel for PET scanning
Exclusion Criteria:
- Other major psychiatric disorders such as schizophrenia, schizoaffective illness; current drug or alcohol abuse (within past 2 months), or drug or alcohol dependence <6mos ago; anorexia nervosa or bulimia nervosa in the past year; IV drug use or ecstasy use more than two times.
- A first-degree family history of schizophrenia if the subject is less than 33 years old (mean age of onset for schizophrenia plus two standard deviations).
- Significant active physical illness particularly those that may affect the brain or serotonergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease, diabetes, low hemoglobin and malignancy, significant anemic disease or blood loss and the lab parameters platelet count < 80,000.
- Lacks capacity to consent.
- Actively suicidal-begins expressing a plan for suicide during the washout phase or develop suicidal ideation that warrants admission or requires medication or treatment intervention.
- Electroconvulsive therapy (ECT) within the past 6 months.
- Pregnancy, currently lactating; planning to conceive during the course of study participation or abortion in the past two months.
- Metal implants, pacemaker or metal prostheses or orthodontic appliances, the presence of shrapnel
- Current, past or anticipated exposure to radiation, that may include: being badged for radiation exposure in the workplace, participation in nuclear medicine procedures, including research protocols in the last year.
- A neurological disease or loss of consciousness for more than a few minutes
- Medicinal Patch (participants will be asked to remove before MRI)
- Patients who are responding satisfactorily to psychiatric medications, because they will not be washed-out for purposes of this study
- A documented history of a lack of response to a trial of adequate dose and duration of both lithium and lamotrigine defined as minimal clinical response to lamotrigine 200 mgs for at least 4 weeks or lithium serum levels of at least 0.8 (or dose >= 900 mgs) for at least 4 weeks.
- Patient is unlikely to be able to tolerate medication washout
- Claustrophobia
- Blood donation within 8 weeks of the start of the study.
- History of bleeding disorder or are currently taking anticoagulants.
UNIPOLAR
Inclusion:
- Unipolar patients suffering from a major depressive episode currently or recently (in the month prior to scanning). Patients on psychiatric medication will have failed their current regimen for the treatment of their depression: they will meet criteria for depression, be seeking treatment for it, and have been on an adequate dose of antidepressant or mood stabilizer (as defined by the Antidepressant Treatment Form-see Oquendo et al., 2003) for 4 weeks or more.
- Of sufficient severity to score at least 15 on the first 17 items of the Hamilton Depression Rating Scale or a score of 10 to 14 on the first 17 items of the Hamilton Depression Scale in conjunction with a score of at least 29 on the Beck Depression Inventory.
- Age range 18-65 years.
- Off all psychotropic and other types of drugs likely to interact with serotonin transporters and 5-HT1A receptors for at least 21 days. Allowed short-acting benzodiazepines for distressing anxiety or insomnia (up to 24 hours prior to each PET scan). Patients will be off neuroleptics for 3 weeks and off fluoxetine for 6 weeks prior to study. Off serotonin depleting drugs such as reserpine for 3 months. Patient will also be off anti-coagulant/anti-platelet treatment such as coumadin, with the exception of aspirin for 10 days.
- Willing to travel for PET scanning
Exclusion:
- Other major psychiatric disorders such as schizophrenia, schizoaffective illness; current drug or alcohol abuse (within past 2 months), or drug or alcohol dependence <6mos ago; anorexia nervosa or bulimia nervosa in the past year; IV drug use or ecstasy use more than two times.
- A first-degree family history of schizophrenia if the subject is less than 33 years old (mean age of onset for schizophrenia plus two standard deviations).
- Significant active physical illness particularly those that may affect the brain or serotonergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease, diabetes, low hemoglobin and malignancy, significant anemic disease or blood loss and the lab parameters platelet count < 80,000.
- Lacks capacity to consent.
- Actively suicidal-begins expressing a plan for suicide during the washout phase or develop suicidal ideation that warrants admission or requires medication or treatment intervention.
- Electroconvulsive therapy (ECT) within the past 6 months.
- Pregnancy, currently lactating; planning to conceive during the course of study participation or abortion in the past two months.
- Metal implants, pacemaker or metal prostheses or orthodontic appliances, the presence of shrapnel
- Current, past or anticipated exposure to radiation, that may include: being badged for radiation exposure in the workplace, participation in nuclear medicine procedures, including research protocols in the last year.
- A neurological disease or loss of consciousness for more than a few minutes
- Medicinal Patch (participants will be asked to remove before MRI)
- Patients who are responding satisfactorily to psychiatric medications, because they will not be washed-out for purposes of this study
- A documented history of a lack of response to a trial of adequate dose and duration of both lithium and lamotrigine defined as minimal clinical response to lamotrigine 200 mgs for at least 4 weeks or lithium serum levels of at least 0.8 (or dose >= 900 mgs) for at least 4 weeks.
- Patient is unlikely to be able to tolerate medication washout
- Claustrophobia
- Blood donation within 8 weeks of the start of the study.
- History of bleeding disorder or are currently taking anticoagulants.
- Past unsuccessful treatment of Lithium of adequate dose and duration.
HEALTHY CONTROLS
Inclusion:
- No lifetime history of Axis I disorders
- Age range 18-65 years.
- Willing to travel for PET scanning.
Exclusion:
- Past or present alcohol/substance abuse or dependence; IV drug use or ecstasy use more than two times.
- A first-degree relative with history of major depression, schizophrenia, schizoaffective disorder, or suicide attempt; two or more first degree relatives with a history of substance dependence.
- Significant active physical illness particularly those that may affect the brain or serotonergic system including blood dyscrasias lymphomas, hypersplenism, endocrinopathies, renal failure or chronic obstructive lung disease, autonomic neuropathies, peripheral vascular disease, diabetes, low hemoglobin and malignancy, significant anemic disease or blood loss, and the following lab parameters: platelet count < 80,000
- Lacks capacity to consent
- Pregnancy, currently lactating; planning to conceive during the course of study participation or abortion in the past two months
- Metal implants, pacemaker or metal prostheses or orthodontic appliances, the presence of shrapnel
- Current, past or anticipated exposure to radiation, that may include: being badged for radiation exposure in the workplace, participation in nuclear medicine procedures, including research protocols in the last year.
- A neurological disease or loss of consciousness for more than a few minutes
- Medicinal Patch (participants will be asked to remove before MRI)
- Subjects on drugs or medication that affect the serotonin system
- Claustrophobia
- Blood donation within 8 weeks of the start of the study.
- History of bleeding disorder or are currently taking anticoagulants.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Lithium
Patients in this condition will receive lithium administered as follows: Day 1, 2 and 3, 300 mg bid; Days 4-7 lithium 300 qam and 600 qhs.
Lithium level will be checked as close to Day 7 as possible and titrated to a therapeutic plasma level of 0.8-1.2
mEq/l.
Subjects will not undergo lithium monotherapy if they have a documented history of at least two failed trials of lithium of at least 4 weeks duration with therapeutic blood levels for a major depressive episode
|
Other Names:
|
Other: Lamotrigine
Patients who have not respond to adequate prior lithium treatment while depressed, or who refuse lithium, will be given lamotrigine.
Lamotrigine will be started at 25 mg bid and increased to 50 mg bid after 2 weeks and again increased to 100 mg bid after an additional 2 weeks.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Post-Lithium Treatment Hamilton Depression Rating Scale (HDRS)
Time Frame: 8 weeks
|
Patients will have a Hamilton Depression Rating Scale-24 (HDRS) score obtained at baseline.
Minimum score 0, maximum possible score 75; the higher the score on the scale, the more severe the degree of depression.
Participants must have an HDRS score of at least 15 to be eligible.
After eight weeks of medication treatment, the HDRS score will be reevaluated with the HDRS-24 (and rescanned with PET and MRI).
Participants who have a 50% or greater decrease in their HDRS-24 score will be considered responders (to Lithium treatment).
|
8 weeks
|
Prediction of Treatment Response
Time Frame: 8 Weeks
|
Outcome measures were generated following LASSO linear regression analysis using pretreament HDRS-24 AND..
|
8 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Group Differences in 5-HTT Binding Potential
Time Frame: 8 Weeks
|
Differences in mean of 5-HTT binding potential between patients with depression pre-treatment, post-treatment, compared to healthy volunteers.
Broadly, binding potential is defined as the ratio of the tracer concentration in tissue to the free plasma concentration.
It is a measure of the density of "available" targets (e.g.
5-HTT) & the affinity of the ligand (tracer) to that target.
|
8 Weeks
|
Group Differences in 5-HT1A Binding Potential
Time Frame: 8 Weeks
|
Differences in mean of 5-HT1A binding potential between patients with depression pre-treatment, post-treatment, compared to healthy volunteers.
Broadly, binding potential is defined as the ratio of the tracer concentration in tissue to the free plasma concentration.
It is a measure of the density of "available" targets (e.g.
5-HT1A) & the affinity of the ligand (tracer) to that target.
|
8 Weeks
|
Relationship Between Change in 5-HTT or 5-HT1A Binding Potential Pre- to Post Treatment and Lithium Treatment Response
Time Frame: 8 weeks
|
Linear regression & correlation to assess the relationship between between change in binding potential pre- to post treatment vs. treatment response
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ramin Parsey, MD, PhD, Stony Brook University
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Mental Disorders
- Pathologic Processes
- Mood Disorders
- Bipolar and Related Disorders
- Depression
- Depressive Disorder
- Disease
- Bipolar Disorder
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Membrane Transport Modulators
- Antidepressive Agents
- Anticonvulsants
- Sodium Channel Blockers
- Antimanic Agents
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Lamotrigine
- Lithium Carbonate
Other Study ID Numbers
- 2012-1826-F
- 7R01MH090276-03 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bipolar Disorder
-
ProgenaBiomeRecruitingBipolar Disorder | Bipolar I Disorder | Bipolar II Disorder | Bipolar Type I Disorder | Bipolar Disorder Mild | Bipolar Disorder Moderate | Bipolar Disorder SevereUnited States
-
Rush University Medical CenterThe Ryan Licht Sang Bipolar FoundationCompletedBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar Disorder I | Bipolar Affective DisorderUnited States
-
University of PittsburghNational Alliance for Research on Schizophrenia and DepressionCompletedBipolar I Disorder | Bipolar II Disorder | Bipolar Disorder NOSUnited States
-
Region StockholmKarolinska InstitutetRecruitingBipolar Disorder | Bipolar Depression | Bipolar I Disorder | Bipolar II Disorder | Bipolar Affective Disorder; Remission in | Bipolar Affective Disorder, Currently Depressed, ModerateSweden
-
Hospital de Clinicas de Porto AlegreFederal University of Rio Grande do Sul; Hospital Moinhos de VentoActive, not recruitingBipolar Disorder | Bipolar Depression | Major Depressive Disorder | Bipolar I Disorder | Affective Disorder | Bipolar II DisorderBrazil
-
Medical University of South CarolinaMilken InstituteCompletedBipolar Disorder | Bipolar I Disorder | Bipolar II DisorderUnited States
-
Mayo ClinicCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
University Hospital, Strasbourg, FranceUnknownBipolar Disorder I | Bipolar Disorder II | Rapid Cycling Bipolar Disorder(DSM-IV-TR)France
-
Myriad Genetic Laboratories, Inc.University of MinnesotaCompletedMajor Depressive Disorder, Bipolar I and Bipolar IIUnited States
-
Centre for Addiction and Mental HealthUniversity Health Network, TorontoNot yet recruitingBipolar Disorder | Bipolar Depression | Treatment- Resistant Bipolar Disorder | Type 2 Bipolar DisorderCanada
Clinical Trials on Lamotrigine
-
University of CincinnatiAmerican Epilepsy Society; Epilepsy FoundationCompleted
-
University of Maryland, BaltimoreCompleted
-
GlaxoSmithKlineCompletedEpilepsy, PartialUnited States, Korea, Republic of, Ukraine, Chile, Costa Rica, Russian Federation, Puerto Rico, Argentina
-
University of ChicagoCompletedDermatillomania | Pathologic Skin Picking | Neurotic Excoriation | Psychogenic ExcoriationUnited States
-
University of Maryland, BaltimoreFood and Drug Administration (FDA)Completed
-
University of CincinnatiAmerican Epilepsy Society; Epilepsy FoundationCompleted
-
GlaxoSmithKlineCompleted
-
GlaxoSmithKlineCompletedMental DisordersUnited States
-
GlaxoSmithKlineCompleted